Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Amgen (NASDAQ:AMGN) Stock: Why Biotech Joined Health Care's Down Day

Amgen (NASDAQ:AMGN) shares slipped on Friday, October 2, as biotech stocks joined the broader health-care sector in sitting out a tech-led market rally. No company-specific news was found for Amgen. The California-based biotech, known for medicines in areas such as bone health, cardiovascular disease …

Nitish Kishor | 05 October 2026

McKesson (NYSE:MCK) Stock: Why It Edged Lower After the CVS Deal-Extension Rally

McKesson (NYSE:MCK) handed back some of Thursday's gains on Friday, with no fresh news and health care lagging a market that was busy chasing chips. Shares slipped onto the list of the S&P 500's weaker stocks one day after a strong rally on a …

Nitish Kishor | 05 October 2026

Veeva Systems (NYSE:VEEV) Stock: Why Health-Care Software Lagged as the Sector Finished Lower

Veeva Systems (NYSE:VEEV) sells cloud software built specifically for the life sciences industry. Drugmakers and biotech firms use its tools to manage clinical trials, regulatory filings, quality records and sales andMarketingto doctors. That makes it a technology company whose fortunes are tied closely to …

Nitish Kishor | 05 October 2026

Which of four healthcare moves matters most: Merck's Welireg combination approval, Edwards' pediatric pulmonary valve, Lilly's wider Jaypirca label or Novartis licensing Abogen's mRNA lead asset?

Welireg is an oral inhibitor of hypoxia-inducibleFactor2 alpha, and Lenvima is a tyrosine kinase inhibitor, so the combination attacks two pathways in advanced renal cell carcinoma, the most common kidney cancer. The approval came on its October 4 target date, which indicates an orderly …

Vinay Lochav | 05 October 2026

Which cluster of weekend FDA actions cleared Merck's Welireg plus Lenvima, the first pediatric surgical pulmonary valve and a wider Lilly leukemia label?

Merck & Co., Inc. (NYSE:MRK) gained clearance for Welireg, an oral inhibitor of hypoxia-inducibleFactor2 alpha, in combination with Lenvima for advanced renal cell carcinoma, the most common type of kidney cancer. The decision came on its October 4 target date. Edwards Lifesciences Corporation (NYSE:EW) …

Vinay Lochav | 05 October 2026

How Allergy Therapeutics (LSE:AGY) Is Preparing for the End of Germany's TAV Allergy Programme

Allergy Therapeutics develops, manufactures and sells allergy immunotherapy treatments, which aim to address the underlying cause of allergies rather than just the symptoms. Its registered product portfolio includes Pollinex and Venomil, and it is advancing a pipeline of next-generation treatments, including VLP Peanut. Germany …

Divya Sood | 05 October 2026

How Smith & Nephew (LSE:SN) Is Reshaping Its Debt Maturities With a New 2036 Dollar Bond

Smith & Nephew is a medical technology company listed in London and, through American depositary shares, in New York. It reports threeBusinessunits: Orthopaedics, which includes hip and knee implants; Sports Medicine and ENT; and Advanced Wound Management. The company says it employs about 17,000 …

Divya Sood | 05 October 2026

How hVIVO (LSE:HVO) Is Expanding Into Dermatology and Women's Health Trials Through CRS Berlin

hVIVO is an AIM-quoted clinical trials services company. It runs aQuarantineFacilityin Canary Wharf, London, which it describes as the largest of its kind worldwide, for human challenge trials. It also operates CRS clinical sites in Mannheim and Kiel in Germany, which carry out early-phase …

Divya Sood | 05 October 2026

How DXS International (AQSE:DXSP) Returned to a Small After-Tax Profit as Revenue Dipped

DXS International is quoted on the Aquis Stock Exchange Growth Market under the code DXSP. The company describes itself as a digital clinical decision support business, providing treatment guidelines and guidance to healthcare professionals during patient consultations. Its products include SMART Referral software and …

Divya Sood | 05 October 2026

Moderna (NASDAQ:MRNA) Stock: Why a Nasdaq-100 Promotion Drew Index Buyers

Moderna (NASDAQ:MRNA) shares rallied on Friday after the biotechnology company was flagged to join the Nasdaq-100 index. The inclusion is set to take effect before the open on 9 October 2026, and the prospect of that change was the confirmed catalyst for the move. …

Nitish Kishor | 05 October 2026
Support

Hi! How can we help you today?

Loading…